As of May, 18 AstraZeneca PLC (AZN) EPS Estimated At $0.28

May 17, 2018 - By Edith Ladford

AstraZeneca PLC (NYSE:AZN) Corporate Logo

On May, 18 before the open. Investors wait AstraZeneca PLC (NYSE:AZN) to report its quarterly earnings, according to RTT. Analysts predict $0.28 earnings per share, which is $0.71 down or 71.72 % from 2017’s $0.99 earnings per share. If $0.28 is reported, AZN’s profit will reach $697.23M for 32.59 P/E. Wall Street now forecasts -78.46 % negative EPS growth despite AstraZeneca PLC last quarter’s EPS of $1.30. AZN touched $36.5 during the last trading session after $0.26 change.Currently AstraZeneca PLC is uptrending after 9.03% change in last May 17, 2017. AZN has 3.44 million shares volume. AZN underperformed by 2.52% the S&P 500.

AstraZeneca PLC (NYSE:AZN) Ratings Coverage

In total 5 analysts cover AstraZeneca (NYSE:AZN). “Buy” rating has 4, “Sell” are 0, while 1 are “Hold”. (NYSE:AZN) has 80% bullish analysts. With $42.0 highest and $36.0 lowest target, AstraZeneca has $40 average target or 9.59% above the current ($36.5) price. 6 are the (NYSE:AZN)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. On Monday, March 19 the firm has “Buy” rating by Jefferies given. On Tuesday, February 6 Leerink Swann maintained the shares of AZN in report with “Market Perform” rating. The company rating was maintained by Leerink Swann on Thursday, January 18. On Friday, December 29 the rating was upgraded by JP Morgan to “Overweight”. On Monday, February 5 Bernstein maintained AstraZeneca PLC (NYSE:AZN) rating. Bernstein has “Buy” rating and $42.0 target. The stock rating was upgraded by J.P. Morgan to “Buy” on Friday, December 29.

AstraZeneca PLC discovers, develops, makes, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide.The firm is valued at $90.89 billion. The Company’s marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases.The P/E ratio is 30.8. The companyÂ’s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases.

A couple more AstraZeneca PLC (NYSE:AZN) news were released by: Streetinsider.com which released on May 16, 2018 “AstraZeneca (AZN) Said to Weigh Sale of US Rights to Crestor, Could Fetch Over $1 Billion – Bloomberg”, also Nasdaq.com on May 16, 2018 released “3 Dividend Stocks to Fund Your Nest Egg”, the next Streetinsider.com is “AstraZeneca (AZN) PT Raised to $41 at BMO Capital” on May 15, 2018. Benzinga.com has article titled “AstraZeneca Shares Are Looking Very Weak Right Now”.

AstraZeneca PLC (NYSE:AZN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: